![]() | |
![]() | |
Clinical data | |
---|---|
Pronunciation | /ˌaɪdəˈruːbɪsɪn/ |
Trade names | Zavedos, Idamycin, others |
Other names | Idarubicin hydrochloride, 4-demethoxydaunorubicin, 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a691004 |
Drug class | Anthracycline [1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 97% |
Elimination half-life | 22 hours |
Identifiers | |
| |
Chemical and physical data | |
Formula | C26H27NO9 |
Molar mass | 497.500 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Idarubicin, sold under the brand name Zavedos and Idamycin, is a medication used to treat acute myeloid leukemia (AML) and breast cancer. [2] [3] It is often used with cytarabine. [2] It is given by injection into a vein or taken by mouth. [2] [3]
Common side effects include nausea, hair loss, abdominal pain, diarrhea, bleeding, mouth inflammation, fever, and headache. [2] Other side effects may include heart failure, arrhythmias, bone marrow suppression, high uric acid, liver problems, kidney problems. [2] Use in pregnancy may harm the baby. [2] It is an anthracycline and acts similar to daunorubicin. [1]
Idarubicin was approved for medical use in the United States in 1990. [2] In the United Kingdom 10 mg for injection costs the NHS about £175 as of 2021. [3] In the United States this amount costs about 70 USD. [4]
![]() | |
![]() | |
Clinical data | |
---|---|
Pronunciation | /ˌaɪdəˈruːbɪsɪn/ |
Trade names | Zavedos, Idamycin, others |
Other names | Idarubicin hydrochloride, 4-demethoxydaunorubicin, 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a691004 |
Drug class | Anthracycline [1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 97% |
Elimination half-life | 22 hours |
Identifiers | |
| |
Chemical and physical data | |
Formula | C26H27NO9 |
Molar mass | 497.500 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Idarubicin, sold under the brand name Zavedos and Idamycin, is a medication used to treat acute myeloid leukemia (AML) and breast cancer. [2] [3] It is often used with cytarabine. [2] It is given by injection into a vein or taken by mouth. [2] [3]
Common side effects include nausea, hair loss, abdominal pain, diarrhea, bleeding, mouth inflammation, fever, and headache. [2] Other side effects may include heart failure, arrhythmias, bone marrow suppression, high uric acid, liver problems, kidney problems. [2] Use in pregnancy may harm the baby. [2] It is an anthracycline and acts similar to daunorubicin. [1]
Idarubicin was approved for medical use in the United States in 1990. [2] In the United Kingdom 10 mg for injection costs the NHS about £175 as of 2021. [3] In the United States this amount costs about 70 USD. [4]